MASP-2 Inhibitors
1 drugsAbout MASP-2
MASP-2 (mannan-binding lectin serine protease-2) is a key enzyme in the lectin pathway of the complement system, part of innate immunity. It recognizes carbohydrate patterns on pathogens, triggering inflammation and pathogen destruction via the complement cascade.
MASP-2 is a potential drug target because dysregulation of the complement system is implicated in various diseases. Currently, there is no genetic evidence directly linking MASP-2 to specific diseases.
There is one FDA-approved drug, YARTEMLEA, targeting MASP-2, developed by OMEROS CORP. YARTEMLEA, a biologic (other) modality, was first approved in 2025 for an indication classified as 'other'.
Top MASP-2 Drugs
OMEROS CORP is the only company with an approved drug targeting MASP-2.
Low competition may present an opportunity, but also indicates potential challenges in the target's validation.
MASP-2 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets MASP-2, using biologic (other) modality.
The lack of modality diversity suggests an opportunity for small molecule or alternative biologic approaches.
MASP-2 Clinical Trials 4 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on MASP-2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 3 | 0 | 1 | 2 | 0% |
| Phase 3 | 1 | 0 | 1 | 0 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
MASP-2 Drug Approval Timeline (2025 - 2025)
The first and only drug, YARTEMLEA, was approved in 2025.
Recent approval suggests growing interest, but also limited long-term market data.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on MASP-2. A trial counts if an approved drug acting on MASP-2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.